natgillin/translations-raw huggingface dataset:
Use of a S1P receptor modulator or agonist in the manufacture of a medicament for use in the treatment of an autoimmune disease selected from the list consisting of multiple sclerosis, polymyositis, lupus nephritis, rheumatoid arthritis, inflammatory bowel disease and psoriasis, wherein, prior to commencing the administration of the S1P receptor modulator or agonist at the standard daily therapeutic dosage, said S1P receptor modulator or agonist is administered at a daily dosage which is lower than the standard daily therapeutic dosage during an initial period of treatment, wherein the initial period of treatment is 7 days, and wherein the daily dosage during the initial period of treatment is up to 10 fold less than the standard daily dosage. 
Tvar nazvana 2-amino-2-[2-(4-oktilfenil)etil]propan-1,3-diol u slobodnom obliku ili u obliku farmaceutski prihvatljive soli, ili njenog fosfata formule IIa, [image] pri čemu je R2a jednak H, R3a je OH, Xa je O, R1a i R1b su OH, za uporabu u liječenju multiple skleroze, gdje se, za vrijeme početnog razdoblja liječenja, navedena tvar daje u početnoj dnevnoj dozi od 0.125 mg, kasnije u dnevnoj dozi od 0.25 mg, a zatim se liječenje nastavlja standardnom dozom od 0.5 mg.
The antitumor agent according to any one of [1] to [4], wherein one cycle of an administration schedule, in which, in a period of 28 days, a combination drug containing trifluridine and tipiracil hydrochloride in a molar ratio of 1:0.5 is administered on Days 1 to 5 and on Days 8 to 12, and CPT-11 is administered on Day 1 and on Day 15, is repeated once or twice or more times. 
Antitumorni agens za primjenu u skladu sa bilo kojim od patentnih zahtjeva 1 do 3, gdje jedan ciklus rasporeda administracije, u kojem, u periodu od 28 dana, kombinirani lijek koji sadrži o,a,a-trifluorotimidin i 5-kloro-6-(2- iminopirolidin-1-il)metil-2,4(1H,3H)-pirimidindion hidroklorid u molarnom odnosu od 1:0.5 je administriran na Dane 1 do 5 i na Dane 8 do 12, i CPT-11 je administriran na Dane 1 i 15, je ponovljen jednom ili dva puta ili više puta.
A single chain antibody that can specifically bind to human Sp35 polypeptide (SEQ ID NO:2), wherein the single chain antibody comprises the VL region of the amino acid sequence set forth in SEQ ID NO:434 and the VH region of the amino acid sequence set forth in SEQ ID NO:433. 
Jednolančano protutijelo koje se može specifično vezati na ljudski polipeptid Sp35 (SEQ ID NO:2), naznačeno time što jednolančano protutijelo sadrži područje VL s aminokiselinskim slijedom iznijetim u SEQ ID NO:434 1 područje VH s aminokiselinskim slijedom iznijetim u SEQ ID NO:433.
The method of claim 21 wherein up to 4500 mg amoxicillin and up to 300 mg rifabutin is administered daily. 
Kapsula u skladu s patentnim zahtjevom 21, naznačena time što se svakodnevno primjenjuje do 4500 mg amoksicilina i do 300 mg rifabutina.
The temperature of the WFI was superior to 70° C. The circulation loop flow was set at 583 l·h−1kg−1during 10 mn (5 nm top/down flow and 5 mn down/top flow). 
Temperatura WII je bila veća od 70 *C, Cirkulacijski protok je bio postavljen na 583 L.h'.kg" tijekom 10 min (5 min protoka od vrha prema dnu te 5 min protoka od dna prema vrhu).
The TGFß antagonist for use, the composition, or the kit, according to claim 8, wherein said antibody is a humanized antibody that comprises one or more CDRs of 1D11. 
Antagonist TGFB za uporabu u skladu sa zahtjevom 6, naznačen time što navedeno protutijelo je humanizirano protutijelo koje sadrži jednu ili više CDR-ova od 1D11.
IL-18BP is a soluble protein having a high affinity for IL-18. 
IL-18BP je topivi protein s visokim afinitetom za IL-18.
the heavy chain variable domain of SEQ ID NO:208 and the light chain variable domain of SEQ ID NO:207; or 
varijabilna domena jakog lanca od SEQ ID NO:208 i varijabilna domena slabog lanca od SEQ ID NO:207; ili
The composition according to claim 1 or 2, wherein the amount of carrageenan is comprised between 5% and 25%, more preferably between 10% and 20%, by weight of the composition. A formulation comprising 
Sastav u skladu spatentnim zahtjevom 1 ili 2, pri čemu je količina karagenana sadržana između 5% 1 25%, poželjnije između 10% 120%, u odnosu na masu sastava.
A compound, which is: or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. 
Spoj sukladno zahtjevu 1, s formulom: (JA ili njegova farmaceutski prihvatljiva sol ili stereoizomer.
The first agent and the second agent for the use of claim 1, wherein said treatment or prevention comprises administering a further therapeutic agent and/or radiation therapy, wherein the further therapeutic agent is preferably an anti-neoplastic agent or an anti-tumor antibody or a chemotherapeutic agent, wherein the chemotherapeutic agent is preferably selected from the group consisting of capecitabine, anthracycline, doxorubicin, cyclophosphamide, paclitaxel, docetaxel, cisplatin, gemcitabine, and carboplatin. 
Prvo sredstvo i drugo sredstvo za upotrebu prema bilo kojem od patentnih zahtjeva 1-6, naznačeno time što navedeno liječenje ili prevencija sadrži primjenu dodatnog terapijskog sredstva i/ili zračne terapije, gdje je dodatno terapijsko sredstvo poželjno antineoplastično sredstvo ili antitumorsko antitijelo ili kemoterapijsko sredstvo, gdje je kemoterapijsko sredstvo poželjno izabrano iz grupe koja se sastoji od kapecitabina, antraciklina, doksorubicina, ciklofosfamida, paklitaksela, docetaksela, cisplatina, gemcitabina i karboplatina.
or a pharmaceutically acceptable salt thereof, wherein: is selected from CH3 and CD3; 
H ili njegova farmaceutski prihvatljiva sol, pri čemu: R! je odabran od CH; i CDz;
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (A) 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid i komponenta (B) je odabrana od azoksistrobina i pikoksistrobina.
The present method is mainly aimed for application on human samples. It is therefore preferred that biological sample is human blood or a sample derived from human blood, preferably human serum or human plasma; human cerebrospinal fluid or human lymph. 
Postupak prema bilo kojem od zahtjeva 1 do 6, naznačen time, da biološki uzorak je ljudska krv ili je uzorak izveden iz ljudske krvi, poželjno je to ljudski serum ili ljudska plazma, kao i ljudska moždana (cerebrospinalna) tekućina ili ljudska limfa.
enclosing a sealed capsule into a capsule enclosure space of a beverage production device by a relative displacement of at least two enclosing members which define the capsule enclosure space, 
- < zatvaranje nepropusno zatvorene čahure u obuhvatni prostor oko čahure u uređaju za pripremanje napitka pomoću relativnog pomicanja najmanje dva elementa koji obuhvaćaju čahuru i koji određuju prostor u kojemu se nalazi čahura kada je obuhvaćena;
This adjustment may take the form of the adjustable shaft and/or an eccentric mounting, as generally described with reference to the drive train 82 for the ball spline shaft 40, or a different arrangement 
Ovo podešavanje može biti u obliku podesive osovini i fili ekscentričnog smještaja, čiji je princip objašnjen kod opisivanja pogonskog mehanizma (82) za kuglasto-klinastu osovinu (40), ili na drugi način.
For a conductive floor covering the electrical resistance according to EN 1081 will increase from approx. 0.05-0.1 MΩ to more than 100 MΩ when a traditional top coating is applied. 
Kada se primjenjuje uobičajeni gornji sloj, za vodljivu podnu oblogu električni se otpor sukladno EN 1081 povećava od otprilike 0,05 - 0,1 M22 na više od 100 M2.
A compound of Formula (I) according to claims 1 or 2 wherein both R1 and R2 are hydrogen or one is hydrogen and the other is methyl, ethyl, propyl, tert-butyl,optionally substituted with hydroxy or fluorine, C3-C6 cycloalkyl, optionally substituted with hydroxy or fluorine. 
Spoj formule (I) prema patentnim zahtjevima 1 ili 2 naznačeno time da oba R1 i R2jesu vodik ili jedan jest vodik a drugi je metil, etil, propil, fert-butil, koji može biti supstituiran s hidroksi ili fluorom, C3-C6 cikloalkil, koji može biti supstituiran s hidroksi ili fluorom.
E2187-04 pass rating of at least about 75% and has a FASE rating of less than about 50%. 
E2187-04 od najmanje oko 75% te ima FASE-procjenu manje od oko 50%.
mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionization (CI) mode using a direct exposure probe and ionization was effected by electrospray; values for m/z are given; generally, only ions which indicate the parent mass are reported; and unless otherwise stated, the mass ion quoted is (MH)+; 
(x) maseni spektri (MS) su provedeni pri energijama elektrona od 70 electron volta u kemijsko-ionizacijskom (CI) načinu rada koristeći izravno izlaganje probe a ionizacija je provedena elektrosprejem; dani su podaci ua m/z; općenito, samo ioni koji ukazuju masu roditelja su prikazani; i ako nije drugačije navedeno, mesni ion kojeg se navodi je (MH);
A compound represented by the following structural formula or a pharmaceutically acceptable salt thereof, for use in a method of treating a subject with Fabry disease, the method comprising: 
Farmaceutski pripravak naznačen time da sadrži hemitartratnu sol spoja prikazanog sa slijedećom strukturnom formulom: [image] i farmaceutski prihvatljiv nosač ili sredstvo za razrjeđivanje.
is a single bond when R2 is H, or --- is a double bond when R2 is absent; and 
je jednostruka veza kada Roje H, ili je dvostruka veza kada je R» odsutan; te
a 5- or 6-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from the group consisting of: 
5-člana ili 6-člana monociklička aromatska heterociklička skupina opcionalno supstituirana s 1 do 3 supstituenta odabrana od: atoma halogena, cijano-skupine, i
In one embodiment, an antibody comprises: 
PATENTNI ZAHTJEVI Antitijelo koje se sastoji od:
The method of claim 25, wherein the subcutaneous injection is delivered to the patient with a syringe pre-filled with a pharmaceutical composition comprising the anti-CGRP receptor monoclonal antibody or antigen-binding fragment thereof. 
Protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen za uporabu prema patentnom zahtjevu 3 ili 4, naznačeno time što se protutijelo anti-CGRP receptora ili njegov ulomak koji veže antigen daje pacijentu pomoću jedne potkožne injekcije.
was added and the reaction was stirred at room temperature for 1.5 hours. 
1 reakcijska smjesa je bila miješana na sobnoj temperaturi 1.5 sat.
a bone plate having an upper surface, a lower bone-engaging surface, and a hole extending therethrough from the upper surface to the lower surface, the hole having an inner surface that defines a circumference of the hole, the hole defining a central axis and being configured and dimensioned to receive a bone screw therein, wherein: 
Sustav u skladu s patentnim zahtjevom 1, naznačen time, da dodatno sadrži pločicu za kosti koja ima gornju površinu, donju površinu i veći broj otvora koji se protežu od gornje površine do donje površine.
199,677 the high solubility (exceeding 600 mg/ml) of the active ingredient is disadvantageous from the viewpoint of the layering pelletization. 
199,677 visoka topljivost (veća od 600 mg/ml) aktivnog sastojka je nedostatak s točke motrišta granuliranja nanošenjem sloja.
An intracervical device (ICD) according to any of the foregoing claims from 1 to 9, characterized in that the drug is a drug for target therapy or a chemotherapy drug such as Cisplatin, Carboplatin, Taxol, Taxotere, Topotecan, Irinotecan, Adriamycin, Gemcitabine, Bleomycin, Ifosfamide, Vinorelbine, 5 Fluorouracil, VP 16, Metrotrexate, Mitomycin C, Vincristine, Vinblastine. 
Intracervikalni uređaj (ICD) u skladu s bilo kojim od prethodnih patentnih zahtjeva od 1 do 9, naznačen time što topotekana, irinotekana, Adriamycin-a, gemcitabina, bleomicina, ifosfamida, vinorelbina, 5-fluoruracila, VP 16, metotreksata, mitomicina C, vinkristina, vinblastina.
A compound according to claim 1, wherein: 
Spoj sukladno patentnom zahtjevu 1, gdje:
The method of claim 1, wherein the compound of formula (I) is a compound of formula (Ia): 
Sastav koji sadrži spoj formule (I): ko i smjesu koja se dobiva kombiniranjem spoja formule R,;SR> i trikloroizocijanurne kiseline; gdje
In other forms it may be possible to detach them by, for example, applying pressure to the lug. 
U drugim realizacijama izuma moguće ih je razdvojiti primjerice primjenom tlaka na jezičac.
reacting the antigen-linker with a carrier protein to form a conjugated antigen wherein the antigen is a bacterial capsular saccharide and wherein step a) comprises reacting the antigen with periodate. 
reakcije kompleksa antigen-spojnica s proteinskim nosačem kako bi se dobio konjugirani antigen, gdje je antigen saharid iz bakterijske kapsule, te gdje se korak a) sastoji u reakciji antigena s perjodatom.
The use of donepezil or a pharmaceutically acceptable salt thereof in combination with at least one of (i) fluoxetine, fluvoxamine, paroxetine, sertraline or escitalopram, or a pharmaceutically acceptable salt thereof; or (ii) milnacipran or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of major depression. 
Uporaba donepezila ili njegove farmaceutski prihvatljive soli u kombinaciji s najmanje jednim od spojeva (i) fluoksetin, fluvoksamin, paroksetin, sertralin ili escitalopram ili njihovim farmaceutski prihvatljivim solima; ili spojem (ii) milnacipranom ili njegovom farmaceutski prihvatljivom soli, naznačena time, da se koristi u pripravi lijeka za liječenje teške depresije.
According to a preferred embodiment of the present invention, X2 is an amino acid residue selected from the group consisting of lysine (K) and arginine (R) and/or X6 is alanine (A). 
Sastav za uporabu prema zahtjevu 1, naznačen time, da X2 je aminokiselinski ostatak odabran iz skupine koju čine lizin (K) i arginin (R) i/ili X; je alanin (A).
Determine the absorbance of the clear solution in a 1 cm quartz cell at 610 nm with a suitable spectrophotometer previously standardized using water as a reference. 
Odredi se apsorbancija bistre otopine u 1 cm kvarenoj ćeliji pri 610 nm pomoću prikladnog spektrofotometra prethodno standardiziranog upotrebom vode kao standarda.
The compound for use according to claim 14, wherein the disease or disorder is selected from the group consisting of schizophrenia, delusion disorders, movement disorders, anxiety disorder, obsessive-compulsive disorder, and cognitive function disorder. 
Spoj za upotrebu prema zahtjevu 14, naznačen time što je bolest ili poremećaj izabran 1z skupina koja se sastoji od shizofrenije, halucinogenih poremećaja, poremećaja pokreta, tjeskobnih poremećaja, opsesivno-kompulsivnih poremećaja 1 poremećaja kognitivnih funkcija.
One object of the invention is a method for producing transformed microalgae, comprising transforming said microalgae with a nucleotide sequence operably linked to a promoter that drives expression in said microalgae, wherein said nucleotide sequence encodes a N-acetylglucosaminyltransferase I enzyme that is expressed in the transformed microalgae. 
Metoda u skladu sa bilo kojim od patentnih zahtjeva 1 do 3, gdje navedena transformirana mikroalga dalje sadrži nukleotidnu sekvencu operativno vezanu za pokretač koji pokreće ekspresiju u navedenoj mikroalgi, gdje navedena nukleotidna sekvenca kodira N-acetilglukozaminiltransferaza I enzim (Gnt I) koji je eksprimiran u transformiranoj mikroalgi.
A compound according to claim 1, wherein each L is independently selected from a 5 or 6-membered nitrogen-containing heteroaryl, which is optionally fused to a benzene, preferably wherein L is independently selected from pyridinyl, pyrimidinyl, pyridazinyl, oxadiazolyl, pyrazolyl, thiadiazolyl, pyrazinyl, benzofused thiazolyl, benzofused oxazolyl or benzofused imidazolyl, preferably, L is independently selected from pyridyl and pyrazinyl. 
Spoj prema zahtjevu 1, naznačen time što je svaki L neovisno odabran od 5 ili 6-članog heteroarila koji sadrži dušik, koji je proizvoljno kondenziran na benzen, poželjno pri čemu L je neovisno odabran iz niza koji čine piridinil, pirimidinil, piridazinil, oksadiazolil, pirazolil, tiadiazolil, pirazinil, benzokondenziran tiazolil, benzokondenziran oksazolil ili benzokondenziran imidazolil, poželjno, L je neovisno odabran od piridila i pirazinila.
A pair of DNA molecules comprising: a first DNA molecule and a second DNA molecule, wherein said first DNA molecule comprises at least 18 contiguous nucleotides of any portion of the transgene region of SEQ ID NO:4 or SEQ ID NO:5, or complement thereof, and said second DNA molecule comprises a similar length of a 3' flanking corn genomic DNA region of SEQ ID NO:4, or complement thereof to function as DNA primers or probes diagnostic for DNA extracted from corn plant MON89034 or progeny thereof. 
Par DNA molekula, koje sadrže: prvu DNA molekulu i drugu DNA molekulu, pri čemu se prva spomenuta DNA molekula sastoji od najmanje 18 u nizu poredanih nukleotida od bilo kojeg dijela transgene regije SEQ ID NO: 41li SEQ ID NO: 5 ili njihovih komplementarnih sekvenci, a navedena druga DNA molekula se sastoji od 3* preklapajućih genomskih DNA regija SEQ ID NO: 4 slične duljine, ili njihovih komplementarnih sekvenci za funkciju DNA začetnica ili proba za potvrđivanje DNA 1z biljke kukuruza oznake MON89034 ili njenih potomaka.
The device of claim 1, wherein the at least one fluid discharge nozzle (24a, 24b, 24c, 24d) defines an angle (a, B) with respect to the platform (22) in two different planes. 
Naprava u skladu s patentnim zahtjevom 1, naznačena time što najmanje jedna mlaznica za ispuštanje fluida (24a, 24b, 24c, 24d) definira kut (a, B) u odnosu na platformu (22) u dvije različite ravnine.
Preferably from 0.1 to 0.6 mol/mol. The at least one water-soluble acid provided in step b) is added in one or more steps, preferably in one step to said aqueous calcium carbonate containing mineral slurry. 
Postupak prema jednom od zahtjeva 1 do 8, naznačen time da se barem one kiselina koja se otapa u vodi osigurana u koraku b) dodaje u jednom ili više koraka, poželjno u jednom koraku u navedenu vodenu suspenziju koja sadrži kalcijev karbonat.
Process according to claim 3, wherein an amount of Co in the slag of less than 0.1 wt.% is obtained by feeding a major part of low-cobalt batteries. 
Postupak u skladu sa zahtjevom 3. gdje se količina kobalta u zguri manja od masenog udjela od 0,1% dobiva dovodom većeg dijela baterija s malom količinom kobalta.
n is 2; and one or more of the carbon atoms at positions 3, 4 or 5 of the piperidine ring are linked to a nitric oxide donor group of the formula —X1—X2—X3; or 
u navedenoj skupini koja je donor dušikovog monoksida, X1 je odsutan ili je -O-; X2 je odsutan ili je -(C1-C20)alkilen; X3 je -NO ili -ONO2; i navedeni alkilen je po potrebi supstituiran s jednom ili više -ONO2 skupina.
The method of claim 1, wherein the method further comprises administering sequentially or concurrently a drug selected from the group consisting of an alpha-1-adrenergic receptor antagonist, a beta-adrenergic antagonist, an anticonvulsant, a selective serotonin reuptake inhibitor and a serotonin-norepinephrine reuptake inhibitor. 
Farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 1, koja dodatno sadrži lijek odabran iz grupe koja se sastoji od antagonista alfa-1-adrenergičkog receptora, beta-adrenergičkog antagonista, antikonvulzanta, selijektivnog inhibitora ponovnog preuzimanja serotonina ili inhibitora ponovnog preuzimanja serotonina i norepinefrina.
The present invention furthermore comprises salts of the compounds of the invention, typically, pharmaceutically acceptable salts. 
Ovaj izum, nadalje, sadrži soli spojeva izuma, tipično, farmaceutski prihvatljive soli.
encoding means for encoding the encoding target frame by the first encoding means after the internal state thereof is initialized. An audio signal decoding program for decoding an encoded audio signal using a first decoding means operating under a linear predictive coding scheme and a second decoding means operating under a coding scheme which is different from the linear predictive coding scheme, the audio signal decoding program causing a computer device to function as: 
Kompjutorski program za dekodiranje audio signala koji sadrži naredbe koje, kada ih se provodi na kompjutoru, uzrokuju da navedeni kompjutor dekodira kodirani audio signal uz pomoć prvog dekodera (24), koji radi prema linearnoj prediktivnoj shemi kodiranja, i drugi dekoder (25), koji radi prema shemi kodiranja koja se razlikuje od linearne prediktivne sheme kodiranja, naznačen time što program za dekodiranje audio signala uzrokuje da kompjutorski uređaj funkcionira kao:
The packaged product according to statement 11, wherein the seal has a seal elongation at failure of about 25% to about 100%, preferably the seal has a seal elongation at failure of about 30% to about 90%, more preferably the seal has a seal elongation at failure of about 35% to about 80%, even more preferably the seal has a seal elongation at failure of about 35% to about 55%, as measured in accordance with ASTM F88/F88M-09. 
Pakirani proizvod u skladu s patentnim zahtjevom 9, ili MDO film u skladu s patentnim zahtjevom 10, naznačen time, da brtva ima elongaciju brtvljenja pri prekidu od oko 25 % do oko 100 %, poželjno brtva ima elongaciju brtvljenja pri prekidu od oko 30 % do oko 90 %, a još je poželjnije da brtva ima elongaciju brtvljenja pri prekidu od oko 35 % do oko 80 %, izmjereno u skladu s ASTM F88/F88M-09.
providing at least one former having a fish scale-textured surface and dipping the at least one former into the coagulant solution to coat the at least one former with coagulant; 
davanje najmanje jednog kalupa koji ima površinu teksture riblje ljuske i umakanje najmanje jednog kalupa u otopinu koagulanta da bi se najmanje jedan kalup premazao koagulantom;
According to a preferred aspect of the invention there is provided a conjugate wherein the TNF is linked to the targeting peptide CNGRC through the spacer G (glycine). 
Konjugat namijenjen upotrebi u skladu s patentnim zahtjevom 2 ili 3, naznačen time što je TNF vezan na ciljni peptid CNGRC preko razmaknice G (glicin).
A topical formulation for use according to claims 1-3 in the form of eye drops, wherein the compound of formula 1, 1'; or 1" is dissolved or suspended in a suitable carrier. 
Topikalna formulacija namijenjena za upotrebu u skladu s patentnim zahtjevima 1-3, u obliku kapi za oči, naznačena time što spoj formule I, T ili I" je otopljen ili suspendiran u pogodnoj podlozi,
The pest control device according to claim 8, wherein the viscosity modifier comprises one or more of: xanthan gum, carboxymethyl cellulose, polymethacrylic acid, or sodium salts thereof, guar gum, or polyacrylamide. 
Uređaj za suzbijanje štetočina prema bilo kojem od patentnih zahtjeva od 3 do 6, naznačen time da se modifikator viskoznosti sastoji od jednog ili više sljedećih sastojaka: ksantan gume, karboksimetil-celuloze, polimetakrilne kiseline ili njenih natrijevih soli, guar gume, poliakrilamida.
A salt of formula I may be converted to another salt of the same formula by exchanging the cation. When both the starting material and the salt obtained as final product are sufficiently soluble, such an exchange may be performed by using a cation-exchange resin saturated with the cation desired in the product. 
Sol formule I može se prevesti u drugu sol iste formule izmjenjivanjem kationa, Kada su i polazni materijal i sol dobivena kao finalni proizvod dovoljno otopljeni, ovakva izmjena može se izvesti koristeći kationsku izmjenjivačku smolu zasićenu s kationom koji se želi u proizvodu.